Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 11/20 | 0.69 |
| ▸ | MMP9 | P14780 | 11/20 | 0.69 |
| ▸ | MMP8 | P22894 | 11/20 | 0.69 |
| ▸ | MMP14 | P50281 | 11/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MMP11 | P24347 | 2/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.65 |
| ▸ | MMP7 | P09237 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711383 | 1.00 | NMBR (0.73) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL5381814 | 1.00 | NMBR (0.73) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL5556658 | 0.96 | NMBR (0.74) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL5399966 | 0.94 | NMBR (0.71) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL1285921 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL29401760 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL29935468 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL3808330 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL3265534 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL29386277 | 0.91 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581583-B1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE LTD (SG) | 2022-02-23 | — | — | EP | claimed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240415918-A1 | Polypeptide and its use as a CCK receptor agonist/antagonist | Centre for Regenerative Medicine & Health, Hong Kong Institute of Science & Innovation, Chinese (CN) | 2024-12-19 | — | — | US | disclosed |
| EP-3581583-B1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE LTD (SG) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415918-A1 | Polypeptide and its use as a CCK receptor agonist/antagonist | CCKAR, CCKBR, SCTR | NMBR 387/4885MAPT 2430/4885GAA 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.